Once widely acknowledged as so special that only scientists and clinical specialists need to apply, oncology has become exponentially more clinically targeted and sophisticated over the last decade.
Yet how many other therapy areas have market leaders that don’t even have clinical approved indication in that indication?
Join this Cerner Enviza webinar, held in partnership with pharmaphorum, for a 45-minute, evidence-backed discussion on the paradoxical question that is “How do I succeed in oncology?”
On Wednesday 7th December at 3pm GMT / 4pm CET / 10am EST, experts from Cerner Enviza will debate with industry leaders responsible for oncology’s most successful brands and those making the treatment choices for patients.
The discussion will draw from recent research conducted with oncologists, industry leaders, scientists, behavioural scientists, and social media and semiotics experts
The session will explore:
- The rise and rise of immunotherapy
- What is in the mind of an oncologist as they make treatment decisions
- How oncologists make connections to brands
- The success of branding in immuno-oncology
- Keytruda – an anomaly or the new norm?
- Mapping out how we do it in the future
After the discussion you will be able to download the white paper – The Answer to Cancer: It’s time we embraced the fact that oncologists are not only making treatment decisions based on clinical data, which is broken down into two- and three-minute reads and contains the research results used to power the webinar’s discussions.
Our panel
Michael Gaschler, PhD, Senior Consultant, Oncology, Cerner Enviza
Michael is a senior consultant with Kantar’s Oncology and Specialty Therapeutics group. Michael’s areas of expertise span the clinical and commercial aspects of oncology markets. Michael has extensive experience engaging with clinical development strategy, market trends, and real-world utilization patterns. Michael also has experience with commercial development of oncology assets, including revenue forecasting, brand strategy development, commercial analytics, and insights generation.
Michael earned his Ph.D. in chemistry from Columbia University in the City of New York and a B.S. in integrative biology from the University of Illinois at Urbana-Champaign.
Jeanette Hodgson, Global Head of Qualitative Strategy, Cerner Enviza
Jeanette is the Global Head of Qualitative Strategy at Cerner Enviza with the remit of consolidating, developing and promoting qualitative expertise. She has 25+ years’ experience of global, strategic market research and consultancy, mostly from a healthcare perspective but also from a consumer environment. She has a good understanding of marketing strategy. She also has business leadership experience and is a trained Master NLP practitioner.
Mark Sales, Global Director of Innovation, Commercial, Cerner Enviza
Mark leads global innovation for the commercial function at Cerner Enviza, he has over 20 years’ experience launching and working with ground breaking corporate and product brands on the pharma and agency side.
Mark has a focus on bringing Real World Data through Cerner Enviza’s Electronic Health Records to commercial decision making.
The post Oncology treatment decisions aren’t just based on clinical data appeared first on .
